Insmed (INSM) Reports Q2 Loss of $0.72/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update
August 3, 2017 7:31 AM EDTOn Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month  Plan to Initiate Enrollment of Phase 2 Dose-ranging Study of INS1007 in Non-Cystic Fibrosis (non-CF) Bronchiectasis in the Second Half of 2017 U.S. Food and Drug Administration (FDA) Provides Established Name for Lead Development Program ALIS (amikacin liposome inhalation suspension)
BRIDGEWATER, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) --  Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet... More
